Brontictuzumab companion diagnostic - OncoMed
Alternative Names: NGS assay - OncoMedLatest Information Update: 29 Apr 2019
Price :
$50 *
At a glance
- Originator OncoMed Pharmaceuticals
- Developer MolecularMD; OncoMed Pharmaceuticals
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 28 Jul 2018 No recent reports of development identified for phase-I development in Haematological-malignancies(Diagnosis) in USA
- 14 Jun 2014 Investigation in Solid tumours (diagnosis) in USA (unspecified route)